Beta-blockers are excellent drugs. They're cheap and effective; feature prominently in hypertension guidelines; and remain a sine qua non for coronary artery disease, myocardial infarction, and heart ...

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), ...

Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.

Cytokinetics spent Labor Day weekend in Spain, sharing a big phase 3 win for its lead cardio candidate at the European ...

New American guidelines for chronic coronary disease (CCD) modify management considerations for a heterogeneous group that includes people with or without angina, a history of coronary ...

Beta blockers have been shown to prolong survival in chronic heart failure. It is currently a matter of debate whether any β blocker is superior to the other in terms of improving symptoms, left ...

Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line ...

Research highlights the need to consider mental health impacts when prescribing beta-blockers to MI patients with preserved heart function. Study: Short- and long-term effects of beta-blockers on ...

Beta-blockers are commonly used in the initial treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), despite limited evidence of their efficacy.  The MAPLE-HCM trial compared the ...